ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2289

Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis

Michael Mahler1, Gabriella Lakos1, Tyler Webb1, Alvin Yee1, Leendert A. Trouw2 and Pier-Luigi Meroni3, 1Research, INOVA Diagnostics, San Diego, CA, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Int Medicine, University of Milan, Milano, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, Activity score, autoantibodies, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the recent disease criteria. However, in early RA the sensitivities of ACPA and RF are low underlining the need for additional biomarkers. Additionally, there is a strong need for reliable markers for monitoring of disease activity and treatment response. Recently, antibodies directed against carbamylated antigens were identified. Those anti-CarP antibodies recognize antigens containing homocitrulline which is generated from lysine through chemical modification. This study analyzes the correlation of ACPA fine specificities and of anti-CarP antibodies with disease activity and disease duration.

Methods:

A total of 80 RA patients were tested for anti-CCP2 (CCPlus® Immunoscan, Eurodiagnostica) and anti-CCP3 antibodies (QUANTA Lite CCP3, INOVA), for ACPA fine specificities (to three citrullinated peptides, ACPA 1 – 3) and for anti-CarP antibodies by ELISA using fetal calf serum as the antigen as previously described (Shi et al.). In addition RF (IgM) was determined. Disease activity was accessed using the disease activity score 28 (DAS28).

Results:

ACPA, including anti-CCP2 (p=0.0050) and anti-CCP3 (p=0.0128) antibodies, as well as the ACPA fine specificities showed significant association with disease duration. In contrast, RF and anti-CarP antibodies did not show association with disease duration. Although no correlation between any of the autoantibodies and disease activity (DAS28) reached statistical significance, one ACPA peptide showed some degree of positive (p=0.0734) and anti-CarP antibodies negative correlation (p=0.0734). When those two biomarkers were combined in a score (ACPA peptide 1 divided by anti-CarP) a statistically relevant correlation was found (p=0.0264).

Assay/antibody

Correlation with disease duration

Correlation with DAS28

CCP2

p=0.0050

p=0.1058

CCP3

p=0.0128

p=0.2839

ACPA 1

p=0.0051

p=0.0734

ACPA 2

p=0.0280

p=0.1458

ACPA 3

p=0.0741

p=0.1814

RF

p=0.8178

p=0.1370

CarP

p=0.8700

p=0.0751

ACPA 1 / CarP Score

p=0.0128

p=0.0264

Conclusion:

We confirmed the presence of anti-CarP antibodies in RA using an independent cohort of RA patients from Italy. ACPA, but not RF IgM and anti-CarP antibodies are significantly correlated with disease duration. Combining one ACPA peptide with anti-CarP antibodies in an activity score showed association with DAS28. This score might represent a promising biomarker to measure disease activity, but further studies are needed to verify and validate those preliminary findings.


Disclosure:

M. Mahler,

Inova Diagnostics, Inc.,

3;

G. Lakos,

Inova Diagnostics, Inc.,

3;

T. Webb,

Inova Diagnostics, Inc.,

3;

A. Yee,

Inova Diagnostics, Inc.,

3;

L. A. Trouw,

Janssen Biologics,

9;

P. L. Meroni,

Inova Diagnostics, Inc.,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-anti-citrullinated-protein-and-anti-carp-antibodies-with-disease-duration-and-activity-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences